Alzamend Neuro™ is currently working to transition two therapeutics targeting Alzheimer’s disease (“AD”) and psychiatric disorders from clinical/non-clinical stages and towards full commercialization. Our lead candidate, AL001, is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, for the treatment of Alzheimer’s and other neurodegenerative diseases and psychiatric disorders. On September 11, 2021, a first-in-human Phase I six-month clinical trial for AL001 commenced with the first patients dosed. Topline data for AL001 was reported on December 17, 2021, and the full data set was released in March 2022. The data affirmed that dose-adjusted relative bioavailability analyses of the rate and extent of lithium absorption in plasma indicate that AL001 at 150 mg dosage is bioequivalent to the marketed 300 mg lithium carbonate product and the shapes of the lithium plasma concentration versus time curves are similar. AL001 salicylate plasma concentrations were observed to be well-tolerated and consistently within safe limits and the safety profiles of both AL001 and the marketed lithium carbonate capsule were benign. In May 2022 we initiated our Phase II multiple-ascending doze study in Alzheimer’s patients. Our second candidate, AL002, is a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine which seeks to restore the ability of the patient’s immunological system to combat Alzheimer’s. The proposed mechanism of action of AL002 is through the pulsed-Dendritic Cell (“DC”) activation of T-cells that stimulates the immune system, resulting in the clearance of brain amyloid. On September 30, 2021, we announced that we received a written response from the FDA to our meeting request relating to our Type B Pre Investigational New Drug (“IND”) application pursuing a combined Phase I/Phase II study as a path for our planned clinical development of AL002. We plan on submitting an IND during the third quarter of 2022. There are no profound treatments today for Alzheimer’s disease and psychiatric disorders. With AL001 and AL002, the Company believes that we can change that.